Tempus AI, Inc TEM announced the expansion of its collaboration with Takeda Pharmaceutical Company Limited TAK. The tie-up expansion aims to enhance Takeda’s oncology research and development (R&D) efforts.
The latest announcement of an expanded partnership is expected to significantly boost Tempus’ biological modeling capabilities and solidify its foothold in the niche space.
Likely Trend of TEM Stock Following the News
Following the announcement on Sept. 26, 2024, shares of the company moved nearly 3.8% north to $53.84 till last trading.
Historically, the company has gained a high level of synergies from its partnerships and expertise in AI-enabled advancements in precision medicine. We expect market sentiment on the stock to continue to remain positive around this announcement, too.
Meanwhile, Tempus currently has a market capitalization of $8.31 billion. It has a current ratio of 3.70, higher than the industry’s 2.22. In the last reported quarter, TEM delivered a negative earnings surprise of 6.8%.
Rationale Behind the Expansion of Tempus’ Collaboration
Tempus and Takeda had earlier collaborated that leveraged Tempus’ de-identified multimodal datasets. The latest agreement is expected to expand upon that work.
Per Tempus, its multimodal real-world datasets and biological modeling capabilities will likely be combined by Takeda to advance its pipeline of cancer therapeutics. The pipeline includes antibody-drug conjugates and gamma delta T-cell therapies, among others. Takeda researchers will use Tempus’ analytics platform, Lens, to gain real-time access to de-identified patient records and a suite of AI-enabled tools to accelerate critical insights for its drug development efforts.
It is worth mentioning that initial work has resulted in research that will be presented at an upcoming medical congress.
Additionally, the two companies have also commenced a multi-phase biological modeling project leveraging one of the largest repositories of patient-derived tumor organoids in the world.
Per Tempus’ management, the collaboration is expected to assist in efforts to accelerate Takeda’s growing oncology therapeutic pipeline, which may lead to the next generation of cancer treatments.
Industry Prospects in Favor of TEM
Per a report by Precedence Research, the global cancer therapeutics market is expected to be worth around $393.61 billion by 2032 from $164 billion in 2022, witnessing a CAGR of 9.2%. Factors like the rise in the prevalence of cancer cases and cancer research and an increase in the adoption of gene therapies and personalized medicine are likely to drive the market.
Given the market potential, the latest expanded collaboration is expected to provide a significant boost to Tempus’ business.
Tempus’ Recent Developments
This month, Tempus announced a multi-year collaboration with BioNTech SE. Under the collaboration, Tempus is expected to provide analytical support and computational biology expertise to BioNTech across its comprehensive R&D oncology pipeline.
Last month, Tempus reported its second-quarter 2024 results, wherein it recorded a robust year-over-year uptick in its overall revenues and data licensing revenues. During the quarter, the company expanded into the minimal residual disease market with the launch of both tumor-naïve and tumor-informed assays.
TEM’s Share Price Performance
Shares of the company have gained 61.5% in the past three months compared with the industry’s 17.4% rise and the S&P 500's 4.3% growth.
Image Source: Zacks Investment Research
Tempus’ Zacks Rank & Stocks to Consider
Currently, TEM carries a Zacks Rank #4 (Sell).
A couple of better-ranked stocks in the broader medical space are DaVita Inc. DVA and Baxter International Inc. BAX.
DaVita, flaunting a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term growth rate of 17.5%. DVA’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 24.2%. You can see the complete list of today’s Zacks #1 Rank stocks here.
DaVita’s shares have gained 17.7% compared with the industry’s 14.2% rise in the past three months.
Baxter, carrying a Zacks Rank of 2 (Buy) at present, has an estimated long-term growth rate of 10%. BAX’s earnings surpassed estimates in each of the trailing four quarters, with the average being 3.7%.
Baxter has gained 17.7% compared with the industry’s 12.8% rise in the past three months.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>Baxter International Inc. (BAX) : Free Stock Analysis Report
DaVita Inc. (DVA) : Free Stock Analysis Report
Takeda Pharmaceutical Co. (TAK) : Free Stock Analysis Report
Tempus AI, Inc. (TEM) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
